NasdaqGS:BNTXBiotechs
Is BioNTech’s (BNTX) Oncology Pivot Rewriting Its Post‑COVID Investment Story?
Recently, BioNTech highlighted its evolution from a COVID-19 vaccine leader into a broader biotech group focused on oncology, underscored by its acquisition of Chinese startup Biotheseus and a follow-on collaboration with Bristol Myers around antibody candidate BNT327 that includes upfront payments and future royalty sharing.
An interesting implication is that BioNTech is now using targeted acquisitions as a platform to secure large-pharma partnerships, aiming to convert its oncology...